% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Selvaraj:127508,
      author       = {D. Selvaraj and V. Gangadharan and C. W. Michalski and M.
                      Kurejova and S. Stösser and K. Srivastava$^*$ and M.
                      Schweizerhof and J. Waltenberger and N. Ferrara and P.
                      Heppenstall and M. Shibuya and H. Augustin$^*$ and R. Kuner},
      title        = {{A} {F}unctional {R}ole for {VEGFR}1 {E}xpressed in
                      {P}eripheral {S}ensory {N}eurons in {C}ancer {P}ain.},
      journal      = {Cancer cell},
      volume       = {27},
      number       = {6},
      issn         = {1535-6108},
      address      = {Cambridge, Mass.},
      publisher    = {Cell Press},
      reportid     = {DKFZ-2017-03531},
      pages        = {780 - 796},
      year         = {2015},
      abstract     = {Cancer pain is a debilitating disorder and a primary
                      determinant of the poor quality of life. Here, we report a
                      non-vascular role for ligands of the Vascular Endothelial
                      Growth Factor (VEGF) family in cancer pain. Tumor-derived
                      VEGF-A, PLGF-2, and VEGF-B augment pain sensitivity through
                      selective activation of VEGF receptor 1 (VEGFR1) expressed
                      in sensory neurons in human cancer and mouse models.
                      Sensory-neuron-specific genetic deletion/silencing or local
                      or systemic blockade of VEGFR1 prevented tumor-induced nerve
                      remodeling and attenuated cancer pain in diverse mouse
                      models in vivo. These findings identify a therapeutic
                      potential for VEGFR1-modifying drugs in cancer pain and
                      suggest a palliative effect for VEGF/VEGFR1-targeting
                      anti-angiogenic tumor therapies.},
      keywords     = {Angiogenesis Inhibitors (NLM Chemicals) / Vascular
                      Endothelial Growth Factor Receptor-1 (NLM Chemicals)},
      cin          = {A190},
      ddc          = {610},
      cid          = {I:(DE-He78)A190-20160331},
      pnm          = {311 - Signalling pathways, cell and tumor biology
                      (POF3-311)},
      pid          = {G:(DE-HGF)POF3-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:26058077},
      pmc          = {pmc:PMC4469373},
      doi          = {10.1016/j.ccell.2015.04.017},
      url          = {https://inrepo02.dkfz.de/record/127508},
}